Stats

Sep4completedIEXbar34.945; simpleATR14=1.1575,ADR14=1.12,20daylow/high33.43/37.92,20dayreturn-3.77255%,annualized20dayvol35.02595%,meanIEXvolume350422.75. Source https://runway.adityaperswal.workers.dev/data/stock-bars ; observations8981/8985/8987. One share costs34.945 beforecosts within49.14fundcap. Illustrative1ATRstop33.7875/1.5ATRtarget36.68125 yieldsnominal1.5RR but notvalidatedfundamentalinvalidations ororders. Stopat20daylow33.43 givesonly1.146RR withsameattainabletarget; do notstretchto37.92. One-share20%gaploss6.989,30%gap10.4835 exceeds8.5099accountbudget; entirefund20%gap9.828 alsoexceeds. Stopnotguarantee,whole-shareextendedhoursstillcannotboundgap. Premises: affordableordinaryrange,unknownbinarytail,no remainingregularsessionbeforeSep8 06:15ETERS https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat . Conclusionnoorderorstoprequested. Positivepricecontext would notrepair missingeventedge. Rangeestimates arepartialvenue,historical,notexecutablequotes.

Preregisterednote652; numpyOLS dailyROIVreturn=a+bSPYreturn,all-adjustedIEXbars2022-Jan3 throughSep4 2026 https://runway.adityaperswal.workers.dev/data/stock-bars . Chronological2022–24train752pairedreturns beta1.09843,correlation.32355,R2.10468,intercept.04914%/day;2025–Sep4 2026holdout420 beta.91825,corr.39021,R2.15226,intercept.21894%/day. ROIVmean/std daily .09205/3.73385% train,.28739/2.46271%holdout. Premises: lowR2 andlargeidiosyncraticdispersion; clinicaleventisticker-specific. Conclusion macroprintsdescribecontext,notPHocuslikelihood orforecastalpha. Intercepts arein-sampledescriptivefitswithin eachpartition,notout-of-sampleforecasts orcausal abnormalreturnestimates. Countercase broaderisk-oncouldmatter; beta near1supports someexposure butonly10–15% varianceexplained. No statisticalsignificanceorregimestabilityclaimed. Survivorselectedsingleissuer,newscontamination,partialIEXandadjustmentrevisionslimitgeneralization. Requireprospectiveeventdata rather thanrepeatedqueriescreatingfalseindependence; allocation0.

Premises: 1 Sep6 issuer fixes Sep8 ERS06:15ET and investorcall08ET: https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat . 2 Sponsor registry https://clinicaltrials.gov/api/v2/studies/NCT06635850 lastupdatedFeb20 has135actualparticipants,randomizedparallel/quadruplemasking,week16PVRprimary,6MWTdistance/NTproBNPsecondaries. Feb6 sponsor https://www.pulmovant.com/press-release-february-6-2026 describedapproximately120; actual count andlaterdate explain difference. EstimatedDecembercompletion is stale relative to Septembernotice; it does not negate presentation, but actualcutoff andcompleteness must be verified. 3 Aug6 10Q https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm June30cash/securities3842.082m,quarterCFOoutflow270.504m (+32.35%YoY),SBC83.342m,repurchases206.729m. Burnrate annualized1082.016m; static cash/burn14.20quarters is arithmetic,notforecast. Subsequent July8Genevant771.6mreceipt is separate fromJune30cash; total950mrecipient amount includesArbutus. Pulmovantownership97%basic/90%FD. July31shares722323015 timesSep4IEX34.945 implies25.242bnmixed-dateequityvalue; June30grosscash5.319/share or15.22% ofthatvalue,notparentNAV. 4 BrepocitinibalreadyapprovedAug27 https://investor.roivant.com/news-releases/news-release-details/priovant-announces-fda-approval-lisrayatm-brepocitinib-adults ; earlier10QpendingQ3language is superseded. CONCLUSION prospectivePHocusreviewonly,size0. Attack: strongcash andacutePVRmechanismcouldsupportdevelopment, but neither establishes sustainedfunctionalbenefit orcommercialeconomics. Valid inference distinguishes finance,physiology andpayoff; soundness limited by sponsorreporting,one-quarterburn,minorityinterests andno completevaluation/reimbursementmodel. Facts end atfilings/design; successprobabilitynotestimated.

Primary date observations8954–8975 contain individual source URLs and claim dates. Premises: 1 NYSE https://www.nyse.com/trade/hours-calendars closesSep7; next regularopenSep8 09:30ET. 2 ROIV Sep8 ERS06:15ET precedes08ETcall (https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat); INBX08ETcall, ABM/UNFI morning also precedeopen. No regular-session entry/exit window remains for these. 3 Sep8afterclose BRZE/CASY/AVO and date-onlyGME, Sep9beforeopenCHWY/ASO, Sep9TYRA/IRD08ETcalls and ITX.MCdate-only provide at most one remaining US session; none inherits a tested multi-session run-up. 4 GMEpreannouncedAug31; confirmation is not unanticipated information. CONCLUSION retain research-only calendar and zero pre-open orders. Strong counterargument: extended-hour runups or one-session trades could work, but no own costed evidence estimates that edge and earliest news is uncertain. Inference valid under mandate's evidence requirement; soundness limited by selected universe and incomplete FDA dynamically populatedcalendar, not proof no other events exist. Macro: Sep8 CensusQFR10ET,NYFedSCE11ET,Fedcredit15ET; Sep9 BLSJuneECEC/CensusQ2QSS10ET,EIASTEOdate-only. PPI/CPI and holiday-delayed petroleum are Sep10/11, not Sep8/9. https://www.census.gov/economic-indicators/calendar-listview.html ; https://www.newyorkfed.org/research/calendars/i-sep26.html ; https://www.federalreserve.gov/newsevents/2026-september.htm ; https://www.bls.gov/schedule/2026/09_sched.htm ; https://www.eia.gov/outlooks/steo/outlook.php ; https://www.eia.gov/petroleum/supply/weekly/schedule.php . No Catalyst monitor due. Other funds' due monitors are outside thisbook; do not resolve them. Explicit freshaccess gap CASY PDF403, issuerindex corroborates prior date. Positive operational/clinical evidence changes watch status only; entry also needs new independent net validation, executable quotes and pre-event exit.

Start$49.14fundcash/$850.99account,zeroopen/queued;goalrepeatablenetpre-eventgains. Bindingconstraintvalidatedexecutableedge,not$349.01monthlyshortfall. NUMBEREDPREMISES:1 Aug26issuer https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Fiscal-2027-First-Quarter-Earnings-Results-on-September-23-2026/default.aspx confirmsSep23morning;fixedpaperwindowSep16open/Sep21close,notentrytoday.2 Frozen23eventtest613 holdsout10,net+.567%but25bpslip-2.405%;meanCI[-1.408,+.925]% failsconfidence.3 IndicatorgroupsN4–6andR2-2.733cannotrepairvalidation;15minexitproxy+2.845%/stress-.194% isnotrobust.4 Simulation100000paths from857trainingdays mean-.225% andunestimatedgaprisk; numericpointKellynotional48.29% isnotsizingpermission.5 OnewholeGIS38.28fitsfundcap,butstopatsupport/attainabletargetRR.957fails1.5;freshquotesnotavailable. CONCLUSIONnoPROPOSE/EXIT/ADJUST/FUND;adoptedsize0. VALIDITY: mandatoryconfidence/costconditionsfail,soabstentionfollows. SOUNDNESS: singlechosenissuer,smalldependentholdout,3yearclusters,missingprints,partialvenueIEX,earliestnews/preannouncementcensusincomplete,15minquotes/extendedhoursmissing;notuniversalproofrunupslose. Attack1earlynews/datechangepossible->reverify;2 truepositivesmalledgecouldexist->prospectivevalidationneeded;3higherresolutionquotesmightimproveexecution->donotassume;4regimecouldchange->newdata notresampling;5 supportneednotbeonlyinvalidationbutdonotchooseafterseeingreturns. Who benefitsfromunsupportedturnover:spreadrecipients;cashavoidsnewcosts,preservescapital,allowsprospectivelearning. Firmoperatingimprovementcouldchangethesisbutdoesnotidentifywinprobability. ExistingGISearningsreviewjob30;monitorcap20/newjobcap5rejected additions. Replaceknowntruncatedjob9withtested1591charcombinedprimarycollector48;queued96x240min,firstsavedoutputpending. Next08UTCverify48actualtimestamp+END beforeclaimingdelivery. Marketwidepriorcensus informedGISselection;thisrunisoneboundedquantdeepdive,notnewexhaustivemarketscreen. Noholdingsneedexits. Allfiguresobservationsandanalyses586/613/614/617/619–624;code/resultsarchive15verifiedpartsnotes612–626.

Executed node /app/agent/dist/backtest.js --symbols GIS --strategy momentum --lookback20 --days1825 (actual flags '--lookback 20'). 1252IEXdailybars,60closedtrades,return-1.755185%,DD27.710039%,win35%,avgtrade-.085484%;buyhold-35.533850%. Engineinspected:signals usecurrentcloseandfillthatclose, nofees/slippage, nochronologicalholdout. Thereforediagnosticonly andnotvalidateddeployablestrategy. Requested CLIcheckcompleted; relevantcostedOOSisGIS eventtest613 withvectorbt,notthisgenericmomentumresult. Source https://runway.adityaperswal.workers.dev/data/stock-bars , cli bars.js feediex/unadjustedspecdefault;outputresearch/cli.json. Do not rank-choose genericrulebecauseitoutperformeddecliningbuyhold;nomandatedeventfilterandnegativegrossreturn.

Premises: July1financialbaseline https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-Reports-Fiscal-2026-Fourth-quarter-Adjusted-Results-in-Line-with-Company-Expectations/default.aspx ;Aug19conference https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Remarks-at-Barclays-Global-Consumer-Staples-Conference-on-Sept--8-2026/default.aspx ;Aug26earningsnotice https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Fiscal-2027-First-Quarter-Earnings-Results-on-September-23-2026/default.aspx . FIRST: Sep8publiccommentarycouldchangeSep23expectations; strongerreportedgrowthmayalsoreflectcalendar/divestiture/timing ratherthanenddemand. SECOND: sustainedorganicvolumeandproductivitycouldtranslateintosupplierorders andcash;ifpricecompetitionconsumessavings,retailcustomersbenefitwithoutshareholdermarginexpansion. THIRD: betterFCFcouldsupportcashreturnsandfinancingflexibility; weakerFCFcouldforcecashreturntradeoffs. Theseareconditionalchains,notmeasuredpricecausalityornewcompanyproposals. Beneficiariesofcrediblegrowth:consumers,retailers,issuer/holders;who capturesnetmarginrequiresactualnumbers. Strongbullcasecheapestaplesvaluationandinnovationrecoveryremainspossible; strongestcountercasecostsavingstargetisgrossandpreliminaryconferenceguidancecanremoveinformationnovelty. No numericcausalapprovalorstockwinprobabilityassigned. Analysttargetsdiscardedasnotdefiningourfour-sessionpayoff. Flatbookmeansnothrough-eventholdingreason; nofundcreationedgefound.

Numpyseed9070601,100000four-sessioniidpathsfrom857validtraining2020–23dailyreturns,excludezero/missingadjacentprints. LatestATR/price definesdailyendpointstop-3.0163%/target+4.5245%,checkstop/targetfirst,stopatbreachedendpoint/targetcapped,elsefourthendpoint;costfactor .999*.9995/(1.001*1.0005). Base mean-.225076%,win47.193%,targetfirst4.568%,stopfirst11.943%,time83.489%. On49.14fundnotional mean-$0.11060,p05-$2.05044. Independentassumed20%negativegap atfirstendpoint with1/5/10%windowhazard -> means-.416103/-1.219721/-2.190210%;loss>$8.5099 probability .951/4.947/9.801% atfullfund;thesehazardsarenotestimated. 0/25/50/100%fundsizinggrid recorded8524–8527;0sizehas0dollarloss. Notdatedeventforecast:poolcontainsalltrainingdaysandhistoricalnews,addedgapcoulddoublecount;dailyendpointbarriersmissintraday/15minchecks;100000pathsarenot100000independentevents. Calendarholdout p=.6,avgwin.02035497,avgloss.02779982 -> quarterbinaryKellyNOTIONAL=.25*(p/loss-(1-p)/win)=.482913;risk-unitformula .25*(p-(1-p)/(win/loss))=.0134249 isdifferentunit,notnotionalfraction. UnderstressedcostsnotionalquarterKelly=-.856486 ->clip0. NoKellyestimateadopted:CIcrosses0,coststressnegative;actualsize0. Source https://runway.adityaperswal.workers.dev/data/stock-bars ; code research/analyze.py; observation8521–8527.

IEX all-adjusted completedSep4 bar38.28;SMA20/50 39.5215/37.6946,20sessionreturn+3.796095%,ATR14 simpleTR1.154643,ADR14 high-low1.033214,20dayvol33.661113%annualized,20sessionIEXavgvolume533094. Source https://runway.adityaperswal.workers.dev/data/stock-bars ; these arenotNBBO/consolidatedrange. Low/high20=36.47/42.19. Frozenillustrative1ATRstop37.125357/1.5ATRtarget40.011964 hasnominalRR1.5beforecosts butstopdoesnotestablishfundamentalinvalidation. Stopatsupport36.47 yieldsRR.956886usingthatattainabletarget;donotstretchto42.19tomanufactureedge. Onewhole share38.28fits49.14cap,planned1ATRloss1.15464<8.5099accountbudget;fullgaploss38.28notbounded. Hypotheticalone-share20%gap7.656beforecosts vsfullfund20%gap9.828exceedsbudget. CurrentpaperentrySep16/exitSep21 beforeSep23issuerdate; noearlyorder. Premisesrangefitsasmalldollartradebutvalidationfails;conclusion0allocation. Strongcounterargumentaffordabilityplusvaluemeanreversioncannotrepairnegativecoststress. Noexistingholdingstoadjust.

Frozen pre-entryclose>SMA50 andpositive20sessionreturn evaluatedwithcalendarT-5/T-2rule,fees5bp/slip10or25bpside. Undefined anyrequiredindicator excludesallfilteredsubgroups,includingneither;3train rowsineligible. Baseline13train/10test. At10bpslip trend/both identical:train4,+1.027424%,win25%;holdout5,+4.812912%,win60%,MTMDD3.502189%. Positive momentum train6,+4.323481%,win33.333%;holdout6,+3.580158%,win50%. Neithertrain4,+2.976194%,win75%;holdout4,-2.908878%,win75%,avgwin1.664604/avgloss7.583938%. High winfrequency concealslosstail. Filters are fixeddiagnostics,notpickedfromOOS;N4–6 cannotvalidatecurrentcombinedsignal. 40mode/split/filter/costoutputs recorded8493–8520 incl complete sweep; no extra optimization. Sep4 close38.28>SMA5037.6946 and20dmom+3.7961%,butbelowSMA2039.5215,so latest regimeisnotuniformlybullish. Counterargumenttrendfiltercouldhaveedge; needsnewindependentevents andcostuncertainty. Source https://runway.adityaperswal.workers.dev/data/stock-bars andissuerdates8020–8043; research/analyze.py .

Fixednote594 prior14sessionATR stop1ATR/target1.5ATR;entryT-5open/timeexitT-2close. Dailybar engineopeninggap atopen,stopfirstifboth,cappedtarget;removeMar2022 undefinedATR->12train/10holdout. Train net+2.222662%,DD4.552563%,win50%;stress-1.391913%. Holdoutdailybar+3.009834%,DD5.771908%,win50%,avgwin2.158221/avgloss1.520104%;stress-.034576%,DD7.152712%. Higher-resolution audit fetched1040RTH15minIEXbars across10holdoutwindows,104each/no pagination;entryopen/finalclose/windowhigh exactly reconcile daily. Atfirst15minclosingtrade beyondbarrier,markexit atthatclose:3stops/3targets/4timeexits. Net+2.845122%,event-endpointDD5.808783%,win50%,avgwin2.299527/avgloss1.685185%;stress-.194420%,DD7.76618%,win40%. Morefavorabletargetfills permittedbycheckclose,notrestinglimit. Noextendedsessiondata,NBBOquotes,latency,filldepthoractual15minvenueclock;notexactexecution. Followupafterseeingdailyresults cannotbeconsideredanindependentlyselectednewedge. Premises:dailybarrieroptimismis material; evencheckproxyfailscostrobustness; unknownfirstnews remains. Conclusionrejectdeployment. Sources https://runway.adityaperswal.workers.dev/data/stock-bars ?symbols=GIS&timeframe=15Min&feed=iex witheventdatesinobservations8528–8537;code research/check_intraday.py. Calendarstudy remainsprimary,never choosevariantbyholdout.

23scheduledpre-earnings windows fromissuerdateobservations8020–8043 andIEX https://runway.adityaperswal.workers.dev/data/stock-bars . Holdout10events mean+.109305% but20,000calendar-yearcluster bootstrap95%meanCI[-1.408228,+.925035]%; only3yearclusters,notpreciseconfidence. Train13mean+.708895%,CI[-.237380,+1.300316]%,4clusters. HoldoutnetGIS minusgrosssamewindowSPYmean-.221269%,versusXLP-.099777%;conservativecost asymmetry,nothedgebacktest. Holdoutnetreturn percentiles0/5/50/95/100: -7.583938/-5.146350/.169236/3.731859/4.767482%. OLS trained on12finiteevents: return= -.10556970 -.02600990*prior20dmomentum +6.67488562*priorATR/open. Holdout10 R2=-2.732571 versusholdoutmeanbenchmark; momentumcorrelationtrain-.051905/holdout+.419999. Coefficientsunstable,notcausal/usableforecast. TrendSMAundefinedin3trainobservations,regressionATR/momentumundefinedin1;donotconflatesamples. Priorpositiveeventedgeunsupported; noweighedapprovalprobability. Wouldrequireindependentlargerprospectiveeventswithnetmeanlowerbound>0andrealisticexecutiontochangesizing. Statisticalresamplingdoesnotcreatenewindependentevents.

Preregistered note594 before payoffs. Issuer notices8020–8043 establish24dates;23usable T-5open/T-2close events:13train2020–23,10chronologicalholdout2024–Jul2026. Exclude2020Julprehistory;2020Sepadvance notice unverified;2020Marprehistory. Require notice beforeentry and positivevolume all4heldsessions. AlpacaIEX all-adjustedbars https://runway.adityaperswal.workers.dev/data/stock-bars ; issuerURLperrecord;calendarproxySPYtradingdates. Vectorbt explicitopenentry/closeexit,flat splits,fees5bp/slip10bp eachside. Train+9.42995%,MTMDD4.25994%,win53.846%,avgwin1.919997/avgloss.704058%. Holdout+.567138%,MTMDD9.341003%,win60%,avgwin2.035497/avgloss2.779982%,mean+.109305%perevent. At25bpslip perside holdout-2.405080%,DD10.958271%,win40%. Independent compoundedcashflow matchesvectorbt<1e-7percentagepoints. No intradayorNBBOexecution claim. Currentcandidate selectedfrompriorbroadcensus,notreturns,but survivorship/issuerselection remain. MissingprintedSMA windows excluded fromfilters,notinvented bearishsignals. Historical earliest-news/preannouncement censusincomplete: these are scheduled-window payoffs,not provenpure no-news runups. Rule rejected for deployment; positivepointestimatecannotrepaircost/uncertaintyfailure. Whole-share stop/target variant separateanalysis,notpromotedbyselectingbestholdout.

July1 issuer https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-Reports-Fiscal-2026-Fourth-quarter-Adjusted-Results-in-Line-with-Company-Expectations/default.aspx gives FY26 OCF2.2bn,capex540m,dividends1.3bn,buybacks500m; rounded derived FCF1.66bn covers dividends1.28x but totalcashreturns1.8bn exceedFCF140m. FY27EPSguide3.00–3.20 implies12.35xmidpoint usingSep4IEX38.28; notDCF/fairvalue. Savings>=750mFY27/3bnthroughFY30 implies25%targetinfirstyear and750mannualaverage, not incrementalnetprofit: issuerexpectsorganicgrowth-1.5to+.5% andoperatingprofit-13to-8%. Premises1 cashsupportsdividend betterthan combinedcashreturns;2 savingspartlyoffsetcostpressures;3 cheapmultiplealone doesnotforecastpre-eventdrift. Counterargument cashrecoveryandcostexecutioncouldrerateequity; requiresrealizedgrowth/FCF,not grosssavings. Validitysupportswatch,notshort. Soundness rounded financials,nonGAAPguide,oldquoteandunmodeleddebt/workingcapital. Pricefeed https://runway.adityaperswal.workers.dev/data/stock-bars .

StartCatalyst49.14cash/account850.99,0open/pending; goalrepeatablenetdated-eventrunups. Bindingconstraintindependentlyvalidatedeventedge,notmonthly349.01shortfall. NUMBEREDPREMISES:1 issuerApr10 https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ confirmsSep11date-only;NYSES ep7holiday https://www.nyse.com/trade/hours-calendars leavesSep8–10butfixedT-5entrySep3passed.2 FDAoriginalletter https://download.open.fda.gov/crl/CRL_NDA218592_20250425.pdf documentsclinicaluncertainty;2026remediationdetailsincompletepublicly,notproofnewpackagefails.3 correctedZircaix https://download.open.fda.gov/crl/CRL_BLA761401_20260410.pdf isnotsecondindependentrejection;sharedsitecausalityunestablished.4 recorded500eventaudittrain0/holdout1,positive10.79849%cannotestimatep/averageL;record503generictrain-32.6185%andholdout+11.7464%doesnotvalidateeventrule.5 record506illustrativeR/R.6683fails1.5,freshquoteunavailable;507assumed5%hazarderasesbootstrapmean. CONCLUSIONnoPROPOSE/EXIT/ADJUST/FUND;adoptedsize0,retaincash. VALIDITY: mandatoryedgeconjunctionfailsregardlessofgoodclinicaloutcome. SOUNDNESS: smallselectedcohort,missingIEXprints,unknownfirstnewstiming,andredactions;notuniversalproofrunupslose. Attack1datecouldchange/earlynewsoccur->reverify;2newdatawouldoverturnclinicalconcernbutnotpriceedge;3approvalcouldhelpgroupconfidencewithoutsharedsite;4 largercohortcouldrevealrealpositiveedge;5 consolidatedexecutionmaybebetterthanIEXbutcannotbeassumed. Evidencechangingallocation:point-in-timecomparableeventsamplewithpositivecostedchronologicalholdoutanduncertaintybound,executablequotes,R/R>=1.5,gapawarelossbudget;reestimatequarterKellythen. Priorunsupportedpositiveedgeunchanged;approvalprobabilityunknown,nofabricatedBayesupdate. ExistingTLXmonitor22andjob33continuefavorable->record/validate,adverse/delayed->cash;noneautomatic. Researchlettersarehistoricalnotnew2026adverseevents;newsourcefetchesnolongerchangedpublicconclusion. Lessonsandnextstepsfollow;completingearlywithin39planned/45hardminutes.

Scenario premises sourced to FDA https://download.open.fda.gov/crl/CRL_NDA218592_20250425.pdf , issuerdeadline https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ , BiPASS https://telixpharma.com/news-views/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway/ andH1 https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/announcement.htm . FIRST: PixclaraapprovalcouldunlocklabelledUSuse;CRL/delaycoulddeferit. Noapprovalprobabilityassigned. SECOND: actualadoptiondependsclinicians,reimbursementanddoseavailability;networkutilizationcouldimprove,butapprovaldoesnotprovepaidvolume or ZircaixCMCremediation. BiPASSprebiopsyprostateuseisanotherproductsetting,notglioma efficacyvalidation. THIRD: improvedcashgenerationcouldfundtherapeuticR&D;delaycouldincreasefinancingdependenceoropportunitycost,whilecash252m/commercialbaseweakenasimpleimminentinsolvencycase. ATMcapacityisoptionality,notevidencealreadyissuedshares. BeneficiariesofsuccesscouldincludeTelix,pharmaciesandpatients;exactthird-partyprofitcaptureunknown,noothercompanyproposal. StrongcounterargumentapprovedproductsandnewconfirmatoryevidencemaymakePixclaraupwardoptionalvalue;thatstilldoesnotcalibratepre-eventpayoff. RejectcausalclaimthatallSep2–4rallyisPixclara;BiPASSnewsonSep1UTCconfoundsit. Statisticalapproval/adoption/stockreturnprobabilitiesaredifferent. Stopschecked15mincannotcapovernightbinaryloss;noholdthroughreasonjustified.

Numpyseed709,100000three-sessioniidpathsfrom170positive-print2026dailyreturns,30bpapproxroundtripdeduction. Descriptivebase mean+.739776%,win53.158%,p05-8.82099%;notanapprovalprobabilityorvalidatedtraderule. Addassumed20%adverseterminalgap independently with0/5/10/20%windowhazard: means+.73978/-.28589/-1.265995/-3.273818%;lossover8.5099on49.14notional .086/3.58/7.014/13.746%. Assumedhazardsarenotestimated;compoundingchoiceisillustrative. Breakevenhazardabout3.7%, showsfragilitynotactualriskestimate. Dailyendpointbarrierproxy at+6.43156%target/-9.62343%stop:targetfirst20.93%,stopfirst4.049%,neither75.021%;cannotcaptureintradayorder,gaps,15minvenueexecutionorbidask. Historicalpoolalreadyincludesnews;addedgapstressmaydoublecountsomehazard. No pathquantitycreatesindependentobservations. Requirededgeunknown,quarterKellynotestimableforevent,size0. Recordsourcesobservations7723 andFDAearlydecisioncounterexample https://ir.telixpharma.com/news-releases/news-release-details/fda-approves-new-prostate-cancer-imaging-agent-gozellixr . NoMonteCarlobuyauthorization.

Sep4IEXclose11.95>SMA20 11.67975>SMA50 11.1868,20sessionreturn+3.82276%;ATR14(simplemeanTR).384286 versusmeanintradayrange.1425;20dayannualizedvol52.4002%. Low/high20=10.80/12.46. Illustrativethesisstopatlow10.80 risks1.15/share; generous2ATRtarget12.71857 gains.76857/share,R/R.66832<1.5 evenbeforecosts; overheadhigh12.46offersonly.51. Notordersorfreshlevels. FoursharesatFridayclosecost47.80≤49.14fundcap,plannedstoploss4.60<8.5099accountcap; fullgaploss47.80notbounded. StaleSep4IEXbid9.84/ask13.63,32.2965%midspread makesfutureexecutionunknown. NoNBBOorconsolidatedADRclaim;IEXsparserange mayunderstateaccessiblewholemarketintradayrange. Combiningtrend+volatility+supportdoesnotfixfailedvalidatededge;rejectsize0. NYSE https://www.nyse.com/trade/hours-calendars Sep7closed leavesSep8–10threepredeadlineUSsessions; fixedT-5alreadySep3, noad-hoclateentry. Dataobservations7678/7720.

AlpacaIEX452barsNov2024–Sep42026,excludezero-volumeandpriorzero-volumeobservations; train173dailyreturns through2025,test170in2026. OLS r_t=intercept+lag20daymomentum+lagTR/close. Coefficients0.00031832,-0.00449544,-0.09196510;trainmomentumcorrelation-.0228925;holdoutR2=-.0226811, worse thanholdoutmeanbenchmark. Holdoutdailymean+.337241%,bootstrap20000resamples95%CI[-.192086,+.877430]%. 1/5/50/95/99percentiles[-8.08934,-4.99560,.12338,6.37649,9.70074]%. Thisisdescriptive,notcausalorcalibratedeventforecast. No independentmarketfactor/ASX-FXadjustment; selectedissuer,regimechange,missingprints andiidbootstrapundercountdependence. Positive2026meanfailsuncertainty anddoesnottransporttoPDUFAwindow. CurrentpublicFDAdata cannotbebackdatedto2025signalformation. Source/dataandfullfiguresobservations7678,7722; reproducible research/analyze_final.py,extra.py.

Premises:1 FDAoriginalNDA218592letter https://download.open.fda.gov/crl/CRL_NDA218592_20250425.pdf documents evidencequalitydeficiencies,notjustsubmissionformalities(observation7457).2 March16resubmission https://telixpharma.com/news-views/telix-resubmits-nda-to-u-s-fda-for-tlx101-px-pixclara-brain-cancer-imaging-candidate/ saysadditionaldata/analysisaddressCRL, butdoesnotpublishenoughdetailtoindependentlytestremediation.3 FDAcorrectedZircaix https://download.open.fda.gov/crl/CRL_BLA761401_20260410.pdf retainsAug272025actiondate; redactionsleaveCMCauditunresolved.4 H1filing https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/announcement.htm arithmetic: grossmargin54.51%,OCFmargin4.82%;46operatingprofitless40otherincome=6m,notformallyadjustedprofit. Cash252m(corrects7421/see7441);600mconvertibles. H2requiredrevenue473–493m,R&D106–146m,notadirectburnforecast. Marketcap/sharecount,currentnetdebt,Pixclaraprice/paidutilizationnotfullyverified;nofalseprecisionDCF. Conclusion:commercialbasecanbufferasinglerejectionbutdoesnotestablishpre-eventmispricing. Countercaseadditionaldata mightfullysatisfyFDA;originalCRLisoldandcannotprovefailurein2026. Validityrequirededgegatefails; soundnesslimitedbyredactions/newdatagap. No supportedsharedmanufacturingsiteconnectionbetweenproducts;cannotclaimabsenceofPixclaraCMCissuesbecauseitsqualitysectionisredacted. Physicianintention100survey/~70%readinessisnotorders. TwoFDAapplicationsusingidenticalstudyarenotindependentclinicalreplication. Sourcesstoppedchangingpublicremediationassessment;unknownapprovaloddsandunitvaluationremainexplicit.

Preregistered20-sessionmomentum;10/40sensitivityreportedwithoutselectingholdoutwinner. Vectorbt laggedclose signal,nextpositive-volumeopen,persistentdesiredposition,flatstart eachsplit,lastopenforcedexit;5bpfee+10bpslippageeachside,25bpstress. TrainNov2024–Dec2025:20day-32.6185%,DD35.5869%,N10,p20%,W6.3481%,L6.0441%; rawquarterKelly-.140422,clipped0. HoldoutJan–Sep42026:+11.7464%,DD22.4831%,N7,p28.5714%,W22.1586%,L4.9969%;stress+9.58875%. Holdout-onlydescriptivequarterKelly3.11595%isNOTadopted: priortrainfails and thisstrategyholdsacrossevents,unlikeCatalystmandate.10/40daytrain-52.0329/-40.3158%;holdout+32.9979/+27.4141%,N10/4. Allsweepvaluesrecordedobservations;unselectedpositiveholdoutsacknowledged. No lossboundfromdailyexits;IEXfirstprintsnotauction/NBBO,zero-volumepricesremainindicatorstalenessrisk. Separateeventaudit500trainN0/holdoutN1; no evidencegenericmomentumtransfers tothree-sessionprePDUFAwindow. Rejectrisk,size0.

Preregisterednote548 beforeeventreturns: enteropen fifthregularsession strictlybeforePDUFA,exitclose secondsessionbefore; chronological first2training,last1holdout. Dates issuer https://ir.telixpharma.com/static-files/9959d5f3-16cc-49fc-89eb-4a4af5b57049 and https://telixpharma.com/news-views/telix-reports-204m-revenue-up-63-yoy/ . IEX452barscheckedagainstSPYsessiondates;vectorbt5bpfees+10bpslippageeachside,25bpstress. GozellixMar17–20 entry17.455/exit17.69 givespaper1.042736%,butexitvolume0 INVALID. PixclaraApr21–24 entry16.75/exit19.38 paper15.354908%,butentryvolume0 INVALID. Do notcounttheirwins or shiftfilldates. ZircaixAug20–25 entry10.96/exit12.18 validpositiveprints2275/2640; holdout+10.798492%,DD2.706111%,win100%,N1;stress+10.466594%,DD2.852198%. Thus eligibletrainN0/holdoutN1; W10.7985%,noobservedloss,calibratedp/averageL/Kelly undefined,size0. Selectedsameissuer/nonindependentproducts,earningsoverlap,incompletefirstnewsarchive and sparseIEX preventtransport. KnownGozellixearlyapproval also preventsclaimfixeddeadlineexitguaranteesnonews. CurrentT-5Sep3alreadyelapsed; donotshrinkruletofitSep8. Positive loneholdout reported transparently, notproof noedgeexists. Artifactresearch/analyze_final.py/final_results.json; observations preservefigures.

Ran node /app/agent/dist/backtest.js --symbols TLX --strategy momentum --lookback20 --days650. 444bars,18trades,return-4.061632%,DD46.722770%,win33.3333%,buyhold-22.753717%. CLI lacks the dated-event filter and this result is fullwindow/no explicit executioncosts or holdout; never use for allocation. It triggers separate vectorbt costed chronological audit recordednext. RawIEX zero-volume bars require gating; firstprint is notopeningauction. No proposedtrade.

Start49.14Catalyst cash/account850.99,flat; goal repeatable net pre-event gains; binding constraint independently validated executable edge. Numbered premises: (1) queried ledger has3closed,zeroopen/pending;20armed own monitors none due through nextSep7 00UTC. (2) Issuer Aug19 https://investor.chewy.com/news-and-events/news/news-details/2026/Chewy-Announces-Fiscal-Second-Quarter-Financial-Results-Conference-Call/default.aspx rechecked Sep6 21:02 confirmsSep9beforeopen,08ETcall; https://www.nyse.com/trade/hours-calendars listsSep7 holiday,leavingone regularsession. (3) Saved preregistered vectorbt backtest38 net holdoutN6 returned-1.719988%,DD14.258614%,p50%,W4.523391%,L4.828695%,mean-.152652% per9-session exposure,95%meanCI[-4.527052,3.687206]%;12train,5bpfee+5bpslippage eachside,Python clippedquarterKelly0. (4) No validated late-entry replacement; prior technical435 R/R1.0337<1.5 uses Fridayreferences, not executablecurrentquotes. Conclusion no proposal/queuedlimit. Validity: required edge conjunction fails even if calendar and affordability pass. Soundness limits: small selected historical sample, revised calendars, IEX firstprints and imperfect exit model; cannot infer all runups lose. Attack premises: ledger could change after retrieval but there are no standing orders; issuer could preannounce but earliernews strengthens no-entry; sixevents may miss a trueedge but uncertainty does not justify positive size; future rally could reward a lateentry but is no exante validation. Own0/3closedwins (two discretionary liquidations) does not calibrate a newrule. Prior remains no supported positive edge; independent comparable net holdout with positive uncertainty bound plus executablequotes/pre-first-news exit would permit re-estimation, while fresh issuer news alone changes watch. Cash benefits future optionality;349.01monthlyshortfall changes no odds. Consequences of unsupported holidayentry: possible pre-news fill -> gap bypassesstop -> capital depletion; cash forgoes upside. New saved jobs27/33 at21:01 and30at20:45 have promised compactcoverage; observations7404/7405 record fullaudit. Latest-onlyfeeds not exhaustive;9still2000chars truncated discovery. Existing5jobs/20monitors retain favorable->record/validate and adverse/delayed->reject/cash branches, no duplicate needed. No new statistical/fundamental/simulation experiment claimed: reuse rejected saved strategy per trading-run scope. No ownobligation until next researchrun; overdue socialFIVE belongs CIO. Finish early ~2minutes into21minuteallowance, preserving journal/report reserve.

Start Catalyst49.14 cash,account850.99,flat; goal repeatable net pre-event gains; binding constraint independently validated executable edge. Premises: (1) queried ledger has3closed,zeroopen/pending;20armed own monitors none due through nextSep7 00UTC. (2) Primary issuer Aug19 https://investor.chewy.com/news-and-events/news/news-details/2026/Chewy-Announces-Fiscal-Second-Quarter-Financial-Results-Conference-Call/default.aspx rechecked this run confirmsSep9before-open,08ETcall; https://www.nyse.com/trade/hours-calendars confirmsSep7holiday,leavingone regularsession. (3) Saved vectorbt backtest38 net holdoutN6 return-1.719988%,DD14.258614%,p50%,W4.523391%,L4.828695%,mean-.152652% per9-session exposure,95%meanCI[-4.527052,3.687206]%; clippedquarterKelly0. TrainingN12,5bpfee+5bpslippage eachside. (4) Savedtechnical435 R/R1.0337<1.5 and no validated one-session replacement; Friday references not live levels. Therefore no proposal or queued limit. Validity: mandatory edge conjunction fails. Soundness: small selected historical sample,execution approximation,calendar revision and regime limits; not proof all run-ups fail. Counterexample future rally could reward entry, but does not establish ex-ante positive net odds. Favorable source update changes watch, not size; positive independent comparable holdout plus executable quotes and pre-first-news exit could change allocation. Cash benefits future book optionality; monthly349.01shortfall supplies no odds. Consequences of unsupported holiday entry: fill before news -> gap bypasses stop -> reduced future capital; cash forgoes potential upside. Delivery audit now verifies job33 lastRun16:45 and completeEND1552chars,closing analysis480 freshness gap; cause of schedule shift unknown, no replacement needed. Existing5jobs/20monitors retained; favorable->record/validate,adverse/delayed->cash branches. Job9 remains truncated media discovery, not exhaustive primary evidence. No new backtest/simulation required to reuse rejected rule; no broader primary sweep claimed. Retrieval and arithmetic actually completed by19:42:06UTC; observation7383 approximate19:43 label was an overestimate, use tool createdAt. Finishing early because action audit resolved;22min planned/45hard ceiling preserved.